Roger E. G. Schutgens

7.5k citations

229 papers · 4.7k indexed · h-index 38

Hematology top 0.2%
Internal Medicine top 0.5%
Genetics top 0.5%
Cardiology and Cardiovascular Medicine top 2%
Surgery top 5%

Co-authors: Douwe H. Biesma G. Roosendaal Kathelijn Fischer Eveline P. Mauser‐Bunschoten Evelien P. Mauser‐Bunschoten Lize F. D. van Vulpen S.C. Mastbergen Fred J.L.M. Haas
Topics: Hemophilia Treatment and Research (129 papers)Platelet Disorders and Treatments (79 papers)Blood Coagulation and Thrombosis Mechanisms (55 papers)
Cited by: Internal Medicine Hematology Genetics
Journals: CirculationSHILAP Revista de lepidopterologíaBlood
Partner nations: Netherlands Germany United States

In The Last Decade

Roger E. G. Schutgens

213 papers receiving 4.7k citations

Peers

Countries citing papers authored by Roger E. G. Schutgens

Since Specialization

Citations

This map shows the geographic impact of Roger E. G. Schutgens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger E. G. Schutgens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger E. G. Schutgens more than expected).

Fields of papers citing papers by Roger E. G. Schutgens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger E. G. Schutgens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger E. G. Schutgens. The network helps show where Roger E. G. Schutgens may publish in the future.

Co-authorship network of co-authors of Roger E. G. Schutgens

This figure shows the co-authorship network connecting the top 25 collaborators of Roger E. G. Schutgens. A scholar is included among the top collaborators of Roger E. G. Schutgens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger E. G. Schutgens. Roger E. G. Schutgens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Current Practice Regarding Bleeding Disorders of Unknown Cause in the Netherlands: A National Survey 2025 ·Haemophilia ·(unknown),(unknown),(unknown),Yvonne Henskens,Maartje van den Biggelaar,Roger E. G. Schutgens,Saskia E.M. Schols,(unknown),Karina Meijer,Paul L. den Exter,Laurens Nieuwenhuizen,(unknown),Marieke J. H. A. Kruip,Marjon H. Cnossen,Floor Heubel-Moenen,(unknown)	0
2	The ‘Stop TPO‐RA in ITP Patients’ study: Clinical and immune modulatory effects of romiplostim tapering 2025 ·British Journal of Haematology ·(unknown),(unknown),Tanja Netelenbos,Marina Kartachova,Roger E. G. Schutgens,Otto Visser,Peter E. Westerweel,Jaap Jan Zwaginga,(unknown),Rick Kapur,Masja de Haas,Leendert Porcelijn,Martin R. Schipperus	0
3	Targeted exome analysis in patients with rare bleeding disorders: data from the Rare Bleeding Disorders in the Netherlands study 2024 ·Research and Practice in Thrombosis and Haemostasis ·(unknown),Annet Simons,(unknown),Marjan M. Weiss,Sanna R. Rijpma,(unknown),Karina Meijer,Marjon H. Cnossen,Roger E. G. Schutgens,Nick van Es,Laurens Nieuwenhuizen,Paul L. den Exter,(unknown),Nicole M. A. Blijlevens,Waander L. van Heerde,Saskia E.M. Schols	4
4	Acquired blood platelet disorder in patients with end-stage heart failure after implantation of a continuous centrifugal-flow left ventricular assist device: A prospective cohort study 2023 ·Research and Practice in Thrombosis and Haemostasis ·(unknown),Roger E. G. Schutgens,Linda M. de Heer,Faiz Ramjankhan,Silvie Sebastian,(unknown),Willem J.L. Suyker,Rolf T. Urbanus	2
5	Clotting factor activity levels and bleeding risk in people with haemophilia playing sports 2023 ·Haemophilia ·(unknown),Ellen Kemler,(unknown),Merel A. Timmer,(unknown),Karin P. M. van Galen,Idske C. L. Kremer Hovinga,Paul van der Valk,Lize F. D. van Vulpen,Roger E. G. Schutgens,Casper F. van Koppenhagen,Janjaap van der Net,Kathelijn Fischer	5
6	Evaluation of the procoagulant state in chronic immune thrombocytopenia before and after eltrombopag treatment—a prospective cohort study 2023 ·Journal of Thrombosis and Haemostasis ·(unknown),(unknown),Albert Huisman,Harry R. Koene,Rob Fijnheer,Noortje Thielen,(unknown),Karin P. M. van Galen,Roger E. G. Schutgens,Rolf T. Urbanus	10
7	Functional decline in persons with haemophilia and factors associated with deterioration 2023 ·Haemophilia ·(unknown),Martijn F. Pisters,Cindy Veenhof,Roger E. G. Schutgens,Merel A. Timmer	0
8	Subclinical synovial proliferation in patients with severe haemophilia A: The value of ultrasound screening and biochemical markers 2023 ·Haemophilia ·(unknown),(unknown),Wouter Foppen,Merel A. Timmer,Roger E. G. Schutgens,S.C. Mastbergen,Floris P. J. G. Lafeber,Pim A. de Jong,Kathelijn Fischer,Lize F. D. van Vulpen	8
9	Can motor proficiency testing predict sports injuries and sports‐induced bleeds in people with haemophilia? 2023 ·Haemophilia ·(unknown),(unknown),Merel A. Timmer,(unknown),Karin P. M. van Galen,(unknown),Paul van der Valk,(unknown),Roger E. G. Schutgens,(unknown),Janjaap van der Net,Kathelijn Fischer	1
10	DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A 2023 ·BMJ Open ·(unknown),(unknown),Toine C. G. Egberts,Karin Fijnvandraat,Ron A. A. Mathôt,(unknown),Marjon H. Cnossen,Roger E. G. Schutgens,Rolf T. Urbanus,Kathelijn Fischer	3
11	The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste 2023 ·Research and Practice in Thrombosis and Haemostasis ·(unknown),(unknown),Carin M. A. Rademaker,Toine C. G. Egberts,Roger E. G. Schutgens,Kathelijn Fischer	10
12	Enhanced hepatic clearance of hyposialylated platelets explains thrombocytopenia in GNE-related macrothrombocytopenia 2022 ·Blood Advances ·(unknown),(unknown),Roger E. G. Schutgens,(unknown),Arnold C. Koekman,(unknown),Silvie Sebastian,Albert Huisman,D.J. van den Heuvel,Hans C. Gerritsen,Suzanne J.A. Korporaal,Marc Bierings,Jasper J. van der Smagt,Mariëlle van Gijn,Rolf T. Urbanus	8
13	Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo‐controlled randomized cross‐over clinical trial 2022 ·American Journal of Hematology ·(unknown),Jean‐Louis Kerkhoffs,Saskia E.M. Schols,Anita W. Rijneveld,Erfan Nur,(unknown),Y. Gandon,Paco M J Welsing,Richard van Wijk,Roger E. G. Schutgens,Wouter W. van Solinge,Joannes J.M. Marx,Tim Leiner,Bart J. Biemond,Eduard J. van Beers	8
14	Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review 2021 ·Clinical Pharmacokinetics ·(unknown),Carin M. A. Rademaker,(unknown),Alwin D. R. Huitema,Roger E. G. Schutgens,Toine C. G. Egberts,Kathelijn Fischer	23
15	Coordinating physiotherapy care for persons with haemophilia 2021 ·Haemophilia ·Merel A. Timmer,(unknown),Roger E. G. Schutgens,Cindy Veenhof,Martijn F. Pisters	7
16	Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study 2021 ·Blood Advances ·Paul van der Valk,Michael Makris,Kathelijn Fischer,Robert C. Tait,Pratima Chowdary,Peter W. Collins,Karina Meijer,Lize F. D. van Vulpen,Eveline P. Mauser‐Bunschoten,Roger E. G. Schutgens	18
17	von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients 2020 ·Thrombosis and Haemostasis ·(unknown),(unknown),(unknown),Roger E. G. Schutgens,Britta A. P. Laros‐van Gorkom,Laurens Nieuwenhuizen,F.J.M. van der Meer,Karin Fijnvandraat,Paula F. Ypma,Moniek P.M. de Maat,Frank W.G. Leebeek,Karina Meijer,Jeroen Eikenboom,Ron A. A. Mathôt,Marjon H. Cnossen,(unknown)	5
18	Movement behaviour patterns in adults with haemophilia 2020 ·Therapeutic Advances in Hematology ·Merel A. Timmer,Cindy Veenhof,P. de Kleijn,Rob A. de Bie,Roger E. G. Schutgens,Martijn F. Pisters	11
19	A Blended Physiotherapy Intervention for Persons With Hemophilic Arthropathy: Development Study 2020 ·Journal of Medical Internet Research ·Merel A. Timmer,Corelien Kloek,P. de Kleijn,(unknown),Roger E. G. Schutgens,Cindy Veenhof,Martijn F. Pisters	11
20	Measuring activities and participation in persons with haemophilia: A systematic review of commonly used instruments 2017 ·Haemophilia ·Merel A. Timmer,Samantha C. Gouw,B. M. Feldman,(unknown),P. de Kleijn,Martijn F. Pisters,Roger E. G. Schutgens,Victor S. Blanchette,Alok Srivastava,Judy Ann David,Kathelijn Fischer,Janjaap van der Net	22

About Roger E. G. Schutgens

Roger E. G. Schutgens is a scholar working on Hematology, Internal Medicine and Genetics, having authored 229 papers that have together received 4.7k indexed citations. Recurring topics across this work include Hemophilia Treatment and Research (129 papers), Platelet Disorders and Treatments (79 papers) and Blood Coagulation and Thrombosis Mechanisms (55 papers). The work is most often cited by research in Internal Medicine (998 citations), Hematology (2.9k citations) and Genetics (988 citations). Roger E. G. Schutgens has collaborated with scholars based in Netherlands, Germany and United States. Frequent co-authors include Douwe H. Biesma, G. Roosendaal, Kathelijn Fischer, Eveline P. Mauser‐Bunschoten, Evelien P. Mauser‐Bunschoten, Lize F. D. van Vulpen, S.C. Mastbergen, Fred J.L.M. Haas, Karina Meijer and A. Tuinenburg. Their work appears in journals such as Circulation, SHILAP Revista de lepidopterología and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact